Table 3.
Impact indicators for DINCH in children (HBM4EU Aligned Study data).
| Study name, Country | N | P95 [μg/L] | Number of participants exceeding the HBM-GV | Percentage participants exceeding the HBM-GV [%] | Extent of exceedance [P95/HBM-GVchildren] |
|---|---|---|---|---|---|
| OCC, Denmark | 300 | 41.8 | 0 | 0 | 0.014 |
| InAirQ, Hungary | 262 | 13.3 | 0 | 0 | 0.004 |
| POLAES, Poland | 300 | 9.4 | 0 | 0 | 0.003 |
| PCB cohort, Slovakia | 300 | 22.2 | 0 | 0 | 0.007 |
| CROME, Greece | 161 | 16.9 | 0 | 0 | 0.006 |
| NAC II, Italy | 300 | 44.6 | 0 | 0 | 0.015 |
| SLO CRP, Slovenia | 149 | 18.8 | 0 | 0 | 0.006 |
| 3xG, Belgium | 133 | 10.6 | 0 | 0 | 0.004 |
| ESTEBAN, France | 286 | 23.2 | 0 | 0 | 0.008 |
| GerES V, Germany | 299 | 25.7 | 0 | 0 | 0.009 |
| SPECIMEn-NL, The Netherlands | 89 | 14.4 | 0 | 0 | 0.005 |
N = number of participants.